1.	[News] Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	Vincent J Cogliano, Emanuela Corsini, Agnès Fournier, Heather H Nelson, Consolato M Sergi, Alexandra M M Antunes, Elizabeth K Cahoon, Guosheng Chen, Talita Duarte-Salles, Eric Engels, Jingqi Fu, Dori Germolec, Reza Ghiasvand, Blánaid Hicks, Bertrand J Jean-Claude, Gopabandhu Jena, Catharina M Lerche, Xilin Li, Angela Lupattelli, Thomas P Ong, Libia Vega, Diana R Withrow, Alistair B A Boxall, Lamia Benbrahim-Tallaa, Aline de Conti, Andrew Kunzmann, Elisa Pasqual, Roland Wedekind, Xiaobei Deng, Yahya Mahamat-Saleh, Azam Majidi, Laia Peruchet-Noray, Julia Rezende Da Silva, Eero Suonio, Susana Viegas, Yue Zhai, Heidi Mattock, Caterina Facchin, Mary K Schubauer-Berigan, Federica Madia	
2.	[News] Lung cancer rates highest among British Bangladeshi men	Elizabeth Gourd	
3.	[Articles] Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study	Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain, Francine M Foss, Boyu Hu, Amer Beitinjaneh, Wen-Kai Weng, Youn H Kim, Michael S Khodadoust, Auris O Huen, Leah M Williams, Anna Ma, Elaine Huang, Avanti Ganpule, Shashwat Deepali Nagar, Parin Sripakdeevong, Erika L Cullingford, Sushant Karnik, Mary-Lee Dequeant, Janki N Patel, Xinyi Shirley He, Ziliang Li, Qiuling Ally He, Joy H Mendonez, Alissa Keegan, Steven M Horwitz	
4.	[News] Bangladesh faces serious air pollution crisis	Manjulika Das	
5.	[Articles] Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial	John H Heinzerling, Kathryn F Mileham, Myra M Robinson, James T Symanowski, Raghava R Induru, Gregory M Brouse, Christopher D Corso, Roshan S Prabhu, Daniel E Haggstrom, Benjamin J Moeller, William E Bobo, Carolina E Fasola, Vipul V Thakkar, Sridhar E Pal, Jenna M Gregory, Sarah L Norek, Xhevahire J Begic, Aparna H Kesarwala, Stuart H Burri, Charles B Simone	
6.	[Articles] De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial	Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, Cheng-Zheng Wang, Xian-Fu Sun, Zhen-Duo Lu, Lian-Fang Li, Chong-Jian Zhang, Min Yan, Ya Wei, Bo Chen, Yue-Qing Feng, Miao Deng, Ming-De Ma, Jennifer K Plichta, You-Wen He, Zhen-Zhen Liu	
7.	[Perspectives] Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types	Karl Semaan, Rashad Nawfal, Elizabeth Nally, Yelena Y Janjigian, Caroline Robert, Solange Peters, Thomas Powles, Toni K Choueiri	

2024-11-29	[News] Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	Vincent J Cogliano, Emanuela Corsini, Agnès Fournier, Heather H Nelson, Consolato M Sergi, Alexandra M M Antunes, Elizabeth K Cahoon, Guosheng Chen, Talita Duarte-Salles, Eric Engels, Jingqi Fu, Dori Germolec, Reza Ghiasvand, Blánaid Hicks, Bertrand J Jea	
2024-11-29	[News] Lung cancer rates highest among British Bangladeshi men	Elizabeth Gourd	
2024-11-29	[Articles] Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study	Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain, Francine M Foss, Boyu Hu, Amer Beitinjaneh, Wen-Kai Weng, Youn H Kim, Michael S Khodadoust, Auris O Huen, Leah M Williams, Anna Ma, Elaine Huang, Avanti Ganpule, Shashwat Deepali Na	
2024-11-29	[News] Bangladesh faces serious air pollution crisis	Manjulika Das	
2024-11-28	[Articles] Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial	John H Heinzerling, Kathryn F Mileham, Myra M Robinson, James T Symanowski, Raghava R Induru, Gregory M Brouse, Christopher D Corso, Roshan S Prabhu, Daniel E Haggstrom, Benjamin J Moeller, William E Bobo, Carolina E Fasola, Vipul V Thakkar, Sridhar E Pal	
2024-11-27	[Articles] De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial	Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, Cheng-Zheng Wang, Xian-Fu Sun, Zhen-Duo Lu, Lian-Fang Li, Chong-Jian Zhang, Min Yan, Ya Wei, Bo Chen, Yue-Qing Feng, Miao Deng, Ming-De Ma, Jennifer K Plichta, You-Wen He, Zhen-Zhen Liu	
2024-11-22	[News] American Lung Association calls for expanded insurance coverage for lung cancer screening	Bryant Furlow	
2024-11-22	[News] Former big tobacco employee no longer part of UK Government cancer advisory committee	Tony Kirby	
2024-11-19	[Articles] Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial	Sujay Vora, Deanna Pafundi, Molly Voss, Matthew Buras, Jonathan Ashman, Bernard Bendok, William Breen, Leland Hu, Sani Kizilbash, Nadia Laack, Wei Liu, Anita Mahajan, Maciej Mrugala, Alyx Porter, Michael Ruff, Terence Sio, Joon Uhm, Ming Yang, Debra Brink	
2024-11-19	[Articles] Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment	Robin Forrest, Mylene Lagarde, Ajay Aggarwal, Huseyin Naci	
2024-11-19	[Comment] The power of three: hypofractionation, protons, and molecular imaging in glioblastoma radiotherapy	Eric A Mellon	
2024-11-19	[Comment] The trade-off between accelerated cancer drug approvals and patient preferences	Dario Trapani, Nirmala Bhoo-Pathy	
2024-11-16	[Articles] The current and future global burden of cancer among adolescents and young adults: a population-based study	Taylor Hughes, Andrew Harper, Sumit Gupta, A Lindsay Frazier, Winette T A van der Graaf, Florencia Moreno, Adedayo Joseph, Miranda M Fidler-Benaoudia	
2024-11-16	[Articles] Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multice	Giovanni Randon, Sara Lonardi, Matteo Fassan, Federica Palermo, Stefano Tamberi, Elisa Giommoni, Carlotta Ceccon, Samantha Di Donato, Lorenzo Fornaro, Oronzo Brunetti, Ferdinando De Vita, Alessandro Bittoni, Claudio Chini, Andrea Spallanzani, Floriana Nap	
2024-11-16	[Comment] Early switch maintenance in gastric cancer: who benefits most?	Tomoki Sakakida, Shigenori Kadowaki	
2024-11-15	[Comment] Patients with head and neck cancer unfit for cisplatin—what next?	Naomi Kiyota	
2024-11-15	[Comment] Retrospective analysis of immunotherapy outcomes in Black patients	Kerry L Reynolds, Pauline Funchain	
2024-11-15	[Articles] Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial	Loren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, Julie A Kish, Steven S Chang, Richard C Jordan, Tian Liu, Minh Tam Truong, Eric W Winquist, Vinita Takiar, Trisha Wise-Draper, Jared R Robbins, Cristina P Rodriguez, Musaddiq J Awan, Beth M Beadle, Chr	
2024-11-15	[Articles] Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study	Sean Miller, Ralph Jiang, Matthew Schipper, Lars G Fritsche, Garth Strohbehn, Beth Wallace, Daria Brinzevich, Virginia Falvello, Benjamin H McMahon, Rafael Zamora-Resendiz, Nithya Ramnath, Xin Dai, Kamya Sankar, Donna M Edwards, Steven G Allen, Shinjae Yo	
2024-11-15	[News] UK Government introduces Tobacco and Vapes Bill	Talha Burki	
2024-11-14	[Articles] Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial	Jean-Marc Classe, Pierre Meeus, Delphine Hudry, Romuald Wernert, François Quenet, Frédéric Marchal, Gilles Houvenaeghel, Anne-Sophie Bats, Fabrice Lecuru, Gwenaël Ferron, Cécile Brigand, Dominique Berton, Laurence Gladieff, Florence Joly, Isabelle Ray-Coq	
2024-11-14	[Comment] Secondary cytoreductive surgery with HIPEC: a promising therapeutic option for recurrent ovarian cancer	Taymaa May	
2024-11-12	[Articles] Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis	Luca Mastrantoni, Marta Chiaravalli, Alexia Spring, Viria Beccia, Armando Di Bello, Cinzia Bagalà, Maria Bensi, Diletta Barone, Giovanni Trovato, Giulia Caira, Giulia Giordano, Emilio Bria, Giampaolo Tortora, Lisa Salvatore	
2024-11-11	[Comment] Investing in cancer care in the UK: why aren't we acting on the evidence?	Zachary J Ward, Rifat Atun, Ajay Aggarwal, Mark Lawler, Hedvig Hricak	
2024-11-08	[Articles] Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial	Sai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, Dong-Xiang Wen, Shan-Shan Guo, Li-Ting Liu, Yi-Fu Li, Mei-Juan Luo, Si-Yi Xie, Yu-Jing Liang, Xue-Song Sun, Zhen-Chong Yang, Xiao-Fei Lv, Dong-Hua Luo, Ji-Bin Li, Qing Liu, Pan Wang, Ling Guo, Hao-Yuan Mo, Rui Sun,	
2024-11-08	[Comment] Locoregionally advanced nasopharyngeal carcinoma: integrating immunotherapy into definitive treatment	Dora L W Kwong	
2024-11-08	[News] Impact of radiopharmaceutical shortage prompts questions on UK resilience	Emma Wilkinson	
2024-11-08	[News] Group of UK MPs urge colleagues to support assisted dying bill	Sharmila Devi	
2024-11-08	[News] New Zealand doctors raise alarm about cancer drugs inequity	Tony Kirby	
2024-11-05	[Perspectives] Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types	Karl Semaan, Rashad Nawfal, Elizabeth Nally, Yelena Y Janjigian, Caroline Robert, Solange Peters, Thomas Powles, Toni K Choueiri	
2024-11-05	[News] Final phase of HPV vaccination campaign launched in Bangladesh	Udani Samarasekera	
2024-11-05	[News] European Commission highlights policies to support return to work for patients with cancer and survivors	Talha Burki	
2024-10-31	[Corrections] Correction to Lancet Oncol 2024; 25: 1188–201		
2024-10-30	[Articles] Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study	Dai Maruyama, Eric Jacobsen, Pierluigi Porcu, Pamela Allen, Kenji Ishitsuka, Shigeru Kusumoto, Tomoko Narita, Kensei Tobinai, Francine Foss, Kunihiro Tsukasaki, Tatyana Feldman, Yoshitaka Imaizumi, Koji Izutsu, Satoko Morishima, Nobuhiko Yamauchi, Junichi	
2024-10-30	[Articles] Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study	Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka, Raul Córdoba, Shigeru Kusumoto, Emmanuel Bachy, Kate Cwynarski, Giuseppe Gritti, Anca Prica, Eric Jacobsen, Tatyana Feldman, Yann Guillermin, Daisuke Ennishi, Dok Hyun Yoon	
2024-10-26	[Corrections] Correction to Lancet Oncol 2024; 25: 1176–87		
2024-10-25	[News] New funding for Indigenous-led cancer research and nationwide clinical trials in Australia	Tony Kirby	
2024-10-19	[Articles] Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis	Antonio D'Alessio, Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip, Sarah Slater, Claudia Angela Maria Fulgenzi, Ciro Celsa, Giulia Francesca Manfredi, Madhava Pai, Robert D Goldin, Stephen C Ward, Maria Isabel Fiel, D	
2024-10-18	[News] US legislation might soon allow easier access to cancer medications	Karl Gruber	
2024-10-18	[News] Renewed collaboration aims to improve cancer outcomes in South America	Manjulika Das	
2024-10-18	[Perspectives] Cancer control in the Commonwealth: a roadmap	Rifat Atun, Bhawna Sirohi, Che Reddy, Mary Gospodarowicz	
2024-10-17	[Articles] Access to diagnostic imaging and radiotherapy technologies for patients with cancer in the Baltic countries, eastern Europe, central Asia, and the Caucasus: a comprehensive analysis	Manjit Dosanjh, Vesna Gershan, Eugenia C Wendling, Jamal S Khader, Taofeeq A Ige, Mimoza Ristova, Richard Hugtenburg, Petya Georgieva, C Norman Coleman, David A Pistenmaa, Gohar H Hovhannisyan, Tatul Saghatelyan, Kamal Kazimov, Rovshan Rzayev, Gulam R Bab	
2024-10-15	[Articles] Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial	Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, Joaquín Casal, Manuel Dómine, Bartomeu Massuti, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier de Castro, David Gómez de Antonio, Iván Macia, Santiago Figueroa, Lu	
2024-10-15	[Personal View] Interchangeability of immune checkpoint inhibitors: an urgent need for action	Michiel Zietse, Roelof W F van Leeuwen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Jolanda E de Boer, Rudy Dupree, Ron H J Mathijssen, Lonneke Timmers	
2024-10-12	[Corrections] Correction to Lancet Oncol 2024; 25: 1310–24		
2024-10-11	[News] UK NHS cancer patients to be among those benefiting from deal with life sciences industry	Tony Kirby	
2024-10-11	[News] The Biden administration curbs cancer drug costs for Medicare patients	Bryant Furlow	
2024-10-11	[News] Abortion restrictions have a negative impact on cancer care	Sharmila Devi	
2024-10-10	[Comment] The hidden barriers to using cancer registration data	Nicola Hughes, Richard Feltbower, Dan Stark	
2024-10-10	[Articles] Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis	Ashley Jackson, Pradeep S Virdee, Sharon Tonner, Jason L Oke, Rafael Perera, Kaveh Riahi, Ying Luan, Sara Hiom, Harpal Kumar, Harit Nandani, Kathryn N Kurtzman, Dyfed Huws, Dawn Allan, Stephanie Smits, Sean McPhail, Eileen E Parkes, F D Richard Hobbs, Mar	
2024-10-09	[Articles] Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis	Harriet Rumgay, Suzanne T Nethan, Richa Shah, Jérôme Vignat, Olalekan Ayo-Yusuf, Pankaj Chaturvedi, Eliete N S Guerra, Prakash C Gupta, Ruchika Gupta, Shiwei Liu, Cecilia Magnusson, Mark Parascandola, Yvette C Paulino, Negar Rezaei, Kamran Siddiqi, Saman	
2024-10-04	[News] ASTRO 2024 Annual Meeting	Smriti Patodia	
2024-10-04	[Articles] Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study	Dianna L Ng, Edda Vuhahula, Asteria H Kimambo, Marie Claire Ndayisaba, Godfrey S Philipo, Beatrice P Mushi, Kenneth E Ho, Alan Paciorek, Zainab Illonga, Li Zhang, Poonam Vohra, Jodi Weidler, Michael Bates, Elia J Mmbaga, Katherine Van Loon	
2024-10-04	[News] Jordan joins the Global Platform for Access to Childhood Cancer Medicines	Elizabeth Gourd	
2024-10-04	[News] Approval of single-use e-cigarettes ban in France	Manjulika Das	
2024-10-02	[Corrections] Correction to Lancet Oncol 2024; 25: 1371–86		
2024-10-02	[Corrections] Correction to Lancet Oncol 2024; 25: 1357–70		
2024-09-30	[Comment] Focus where it matters: turning insights into advocacy	John Christodouleas, Therese Lindé, Gustaf Salford	
2024-09-30	[Comment] Radiotherapy and conflict: from disruption to expansion and hope	Nazik Hammad, Fidel Rubagumya	
2024-09-30	[The Lancet Oncology Commission] Radiotherapy and theranostics: a Lancet Oncology Commission	May Abdel-Wahab, Francesco Giammarile, Mauro Carrara, Diana Paez, Hedvig Hricak, Nayyereh Ayati, Jing Jing Li, Malina Mueller, Ajay Aggarwal, Akram Al-Ibraheem, Sondos Alkhatib, Rifat Atun, Abubakar Bello, Daniel Berger, Roberto C Delgado Bolton, John M B	
2024-09-30	[Comment] Spillover benefits of workforce capacity building in radiotherapy	Wilfred Ngwa, Twalib Ngoma	
2024-09-30	[Comment] Radiotherapy gaps and new frontiers in the Commonwealth	Mei Ling Yap, Danielle Rodin	
2024-09-30	[Comment] Radiotherapy and theranostics in a changing world	Cheryl Lai, Smriti Patodia, David Collingridge	
2024-09-28	[News] AACR highlights advances and threats to US cancer research	Tony Kirby	
2024-09-27	[News] Organisations withdraw from cancer conference over tobacco link	Emma Wilkinson	
2024-09-27	[News] President Biden taking Cancer Moonshot global	Sharmila Devi	
2024-09-20	[News] Families of cancer victims wait for benefits decades after the World Trade Center attack	Karl Gruber	
2024-09-20	[News] ESMO Congress 2024	Cheryl Lai	
2024-09-15	[Articles] Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study	Arun A Azad, Mathias Bressel, Hsiang Tan, Mark Voskoboynik, Aneta Suder, Andrew J Weickhardt, Alexander Guminski, Roslyn J Francis, Javad Saghebi, Nattakorn Dhiantravan, Anthony M Joshua, Louise Emmett, Lisa Horvath, Declan G Murphy, Edward Hsiao, Bavanth	
2024-09-14	[Articles] Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study	Othon Iliopoulos, Ane B Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E Beckermann, Stephane Oudard, Tobias Else, Jodi K Maranchie, Cynthia Muller Goldberg, Wei Fu, Rodolfo F Perini, Yanfang Liu, W Marston Linehan, Ramaprasad Srinivasan, Eric Jonasc	
2024-09-13	[News] Petition to end travel insurance discrimination against people with cancer	Manjulika Das	
2024-09-13	[News] Rising costs of cancer medicines	Sharmila Devi	
2024-09-12	[Articles] Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial	Zikun Peng, Huayi Li, Yunong Gao, Li Sun, Jie Jiang, Bairong Xia, Yi Huang, Yu Zhang, Yu Xia, Yuxin Zhang, Yiyang Shen, Bowen Huang, Jiayu Nie, Xinrong Chen, Xingyu Liu, Cui Feng, Zhen Li, Wei Zhang, Kangjia Tao, Qiuxue Zhang, Shican Duan, Yaheng Chen, Ye	
2024-09-11	[Articles] Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial	Alessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valen	
2024-09-11	[Articles] [89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	Brian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj Master, Andrew M Scott, Charles van Praet, Clement Bailly, Bülent Önal, Tamer Aksoy, Robin Merkx, David M Schuster, Sze Ting Lee, Neeta Pandit-Taskar, Alice C Fan, Phillip All	
2024-09-11	[Comment] Treatment of Richter transformation—immunotherapy to the rescue?	Othman Al-Sawaf, Barbara Eichhorst	
2024-09-06	[Articles] Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	Laura A Dawson, Jolie Ringash, Alysa Fairchild, Paul Stos, Kristopher Dennis, Aamer Mahmud, Teri Lynn Stuckless, Francois Vincent, David Roberge, Matthew Follwell, Raimond K W Wong, Derek J Jonker, Jennifer J Knox, Camilla Zimmermann, Philip Wong, Aisling	
2024-09-06	[News] New developments in tobacco control measures in Europe	Talha Burki	
2024-09-06	[News] European Commission approval for Dutch investment in radiopharmaceuticals	Karl Gruber	
2024-09-02	[Comment] Radiation oncology: a call for papers for ESTRO 2025	David Collingridge, Pierre Blanchard	
2024-08-31	[News] World's first lung cancer vaccine trial launched in the UK	Elizabeth Gourd	
2024-08-31	[News] Continued suboptimal HPV vaccine coverage in the USA	Talha Burki	
2024-08-29	[Policy Review] Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE	Philippe Morice, Giovanni Scambia, Nadeem R Abu-Rustum, Maribel Acien, Alessandro Arena, Sara Brucker, Ying Cheong, Pierre Collinet, Francesco Fanfani, Francesca Filippi, Ane Gerda Zahl Eriksson, Sebastien Gouy, Philipp Harter, Xavier Matias-Guiu, George	
2024-08-23	[News] Medicare drug price negotiations by the US Government	Sharmila Devi	
2024-08-21	[Comment] The UK needs to be a leader, not a lagger, in the global cancer effort	Mark Lawler, Ajay Aggarwal, Julie Gralow, Richard Sullivan, Pat Price	
2024-08-17	[Articles] Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis	Yi Zhao, Ying He, Wei Wang, Qi Cai, Fan Ge, Zisheng Chen, Jianqi Zheng, Yuan Zhang, Hongsheng Deng, Ying Chen, Shen Lao, Hengrui Liang, Wenhua Liang, Jianxing He	
2024-08-17	[News] Peru advances towards universal health care for patients with cancer	Talha Burki	
2024-08-17	[News] Progress in NCD screening in Mongolia	Sharmila Devi	
2024-08-14	[Perspectives] Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe	Mark Lawler, Grazia Scocca, Françoise Meunier	
2024-08-13	[Articles] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial	Emanuel Bührer, Michal Kicinski, Mario Mandala, Madeline Pe, Georgina V Long, Victoria Atkinson, Christian U Blank, Andrew Haydon, Stéphane Dalle, Adnan Khattak, Matteo S Carlino, Andrey Meshcheryakov, Shahneen Sandhu, Susana Puig, Dirk Schadendorf, Rahim	
2024-08-13	[Comment] Measuring success of adjuvant treatment for patients with melanoma	Brent O'Carrigan, Pippa G Corrie	
2024-08-10	[Articles] Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phas	Pierre Vera, Sébastien Thureau, Florence Le Tinier, Philippe Chaumet-Riffaud, Sébastien Hapdey, Hélène Kolesnikov-Gauthier, Etienne Martin, Alina Berriolo-Riedinger, Nicolas Pourel, Jean Marc Broglia, Pierre Boissellier, Sophie Guillemard, Naji Salem, Isa	
2024-08-09	[News] Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS	Elizabeth Gourd	
2024-08-08	[Articles] Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial	Jean-Yves Blay, Quentin Devin, Florence Duffaud, Maud Toulmonde, Nelly Firmin, Olivier Collard, Emmanuelle Bompas, Benjamin Verret, Isabelle Ray-Coquard, Sebastien Salas, Clemence Henon, Charles Honoré, Mehdi Brahmi, Armelle Dufresne, Marc Pracht, Alice H	
2024-08-08	[Articles] Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial	Linda J Williams, Ian H Kunkler, Karen J Taylor, Joanna Dunlop, Tammy Piper, Jacqueline Caldwell, Wilma Jack, Joseph F Loane, Kenneth Elder, John M S Bartlett, J Michael Dixon, David A Cameron	
2024-08-08	[Comment] Who does not benefit from whole-breast radiotherapy and how to find them?	Hans-Christian Kolberg, Cornelia Kolberg-Liedtke	
2024-08-08	[Comment] Imatinib in advanced GIST: if it's working, don’t stop a good thing	Ryan A Denu, Neeta Somaiah	
2024-08-08	[Articles] Cancer incidence and survival for 11 cancers in the Commonwealth: a simulation-based modelling study	Zachary J Ward, Qassi Gaba, Rifat Atun	
2024-08-07	[Articles] Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial	Jana de Boniface, Matilda Appelgren, Robert Szulkin, Sara Alkner, Yvette Andersson, Leif Bergkvist, Jan Frisell, Oreste Davide Gentilini, Michalis Kontos, Thorsten Kühn, Dan Lundstedt, Birgitte Vrou Offersen, Roger Olofsson Bagge, Toralf Reimer, Malin Sun	
2024-08-07	[Comment] Time to abandon axillary lymph node dissection in early-stage breast cancer	Andrea V Barrio	